Evidence map›Paper›PMID 34473693›Full record

ArticlePLoS computational biology2021

Relaxing restrictions at the pace of vaccination increases freedom and guards against further COVID-19 waves.

Simon Bauer, Sebastian Contreras, Jonas Dehning, Matthias Linden, Emil Iftekhar, Sebastian B Mohr, Alvaro Olivera-Nappa, Viola Priesemann

Open access · goldAbstract read
In one paragraph

Article in PLoS computational biology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 41 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
41citing papers in PubMed, 2 pooled it
0.4field-weighted citation impact, top 46% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

41 citing papers in PubMed, 2 syntheses or guidelines pooled it, 4 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Optimizing infectious disease mitigation under dynamic conditions.Proceedings of the National Academy of Sciences of the United States of America · 2026
    Article
  4. Mechanics of pandemics.EClinicalMedicine · 2026
    Review
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Polarimetric imaging for the detection of synthetic models of SARS-CoV-2: A proof of concept.Journal of quantitative spectroscopy & radiative transfer · 2023
    Article
  13. Article
  14. Article
  15. Article
  16. Variation in Global Policy Responses to COVID-19: A Bidirectional Analysis.International journal of environmental research and public health · 2023
    Article
  17. Article
  18. Article
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 4 institutions in 2 countries.

Simon BauerMax Planck Institute for Dynamics and Self-Organization, Göttingen, Germany.ORCID 0000-0001-9359-9419
Sebastian ContrerasMax Planck Institute for Dynamics and Self-Organization, Göttingen, Germany.ORCID 0000-0001-8909-774X
Jonas DehningMax Planck Institute for Dynamics and Self-Organization, Göttingen, Germany.ORCID 0000-0002-1728-2505
Matthias LindenMax Planck Institute for Dynamics and Self-Organization, Göttingen, Germany.ORCID 0000-0001-8439-653X
Emil IftekharMax Planck Institute for Dynamics and Self-Organization, Göttingen, Germany.ORCID 0000-0003-0188-500X
Sebastian B MohrMax Planck Institute for Dynamics and Self-Organization, Göttingen, Germany.ORCID 0000-0002-4721-0561
Alvaro Olivera-NappaCentre for Biotechnology and Bioengineering, Universidad de Chile, Santiago, Chile.ORCID 0000-0001-6053-7019
Viola PriesemannMax Planck Institute for Dynamics and Self-Organization, Göttingen, Germany.
Max Planck Institute for Dynamics and Self-Organization · DELeibniz University Hannover · DEMax Planck Society · DEUniversity of Chile · CL

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Mass vaccination offers a promising exit strategy for the COVID-19 pandemic. However, as vaccination progresses, demands to lift restrictions increase, despite most of the population remaining susceptible. Using our age-stratified SEIRD-ICU compartmental model and curated epidemiological and vaccination data, we quantified the rate (relative to vaccination progress) at which countries can lift non-pharmaceutical interventions without overwhelming their healthcare systems. We analyzed scenarios ranging from immediately lifting restrictions (accepting high mortality and morbidity) to reducing case numbers to a level where test-trace-and-isolate (TTI) programs efficiently compensate for local spreading events. In general, the age-dependent vaccination roll-out implies a transient decrease of more than ten years in the average age of ICU patients and deceased. The pace of vaccination determines the speed of lifting restrictions; Taking the European Union (EU) as an example case, all considered scenarios allow for steadily increasing contacts starting in May 2021 and relaxing most restrictions by autumn 2021. Throughout summer 2021, only mild contact restrictions will remain necessary. However, only high vaccine uptake can prevent further severe waves. Across EU countries, seroprevalence impacts the long-term success of vaccination campaigns more strongly than age demographics. In addition, we highlight the need for preventive measures to reduce contagion in school settings throughout the year 2021, where children might be drivers of contagion because of them remaining susceptible. Strategies that maintain low case numbers, instead of high ones, reduce infections and deaths by factors of eleven and five, respectively. In general, policies with low case numbers significantly benefit from vaccination, as the overall reduction in susceptibility will further diminish viral spread. Keeping case numbers low is the safest long-term strategy because it considerably reduces mortality and morbidity and offers better preparedness against emerging escape or more contagious virus variants while still allowing for higher contact numbers (freedom) with progressing vaccinations.

Indexed as

COVID-19COVID-19 VaccinesMass VaccinationAdolescentAdultAgedAged, 80 and overChildChild, PreschoolEuropean UnionHumansInfantInfant, NewbornMiddle AgedYoung AdultCOVID-19 Vaccines

Identifiers

PMID34473693
PMCPMC8412259
OpenAlexW3133653603

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.